Tonix CEO buys 2,000 shares at $13.79 each

Q: How many TNXP shares did Seth Lederman buy and at what price?

An IRA account associated with Seth Lederman bought 2,000 shares of Tonix Pharmaceuticals Holding Corp. common stock at $13.79 per share on August 27, 2026, according to the Form 4 filing.

Q: What direct TNXP holdings did Seth Lederman report?

Seth Lederman reported 20,001 shares of Tonix common stock held as direct ownership as of August 27, 2026. This is disclosed separately from his IRA and Lederman & Co. indirect holdings.

Q: What is the Lederman & Co. position in TNXP mentioned in the filing?

Lederman & Co. is reported as holding 1 share of Tonix common stock indirectly associated with Seth Lederman. A footnote states he may be deemed a control person of this entity.

Q: Was this TNXP Form 4 trade under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox indicates false, meaning the reported August 27, 2026 purchase was not affirmatively disclosed as being made under a Rule 10b5-1 trading plan.

Tonix Pharmaceuticals Holding Corp. (TNXP) director and Chief Executive Officer Seth Lederman reported buying common stock on August 27, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. (TNXP) director and Chief Executive Officer Seth Lederman reported buying common stock on August 27, 2026. An IRA account associated with him purchased 2,000 shares of common stock at $13.79 per share in an open-market or private transaction, held as indirect ownership. After this purchase, the IRA account held 11,005 shares. Separate from this, he also reported 20,001 shares held directly and 1 share held indirectly through Lederman & Co., for which he may be deemed a control person.

Insider Trade Summary

Net Buyer: 2,000 shares

Net Buy 3 txns

Insider LEDERMAN SETH

Role Chief Executive Officer

Bought 2,000 shs ($28K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, $0.001 par value ^F1	2,000	$13.79	$28K
holding	Common Stock, $0.001 par value	--	--	--
holding	Common Stock, $0.001 par value ^F1	--	--	--

Holdings After Transaction: Common Stock, $0.001 par value — 11,005 shares (Indirect, By IRA Account); Common Stock, $0.001 par value — 20,001 shares (Direct); Common Stock, $0.001 par value — 1 shares (Indirect, Lederman & Co.)

Footnotes (1)

F1. Reporting person may be deemed a control person of this entity.

Key Figures

Common shares purchased: 2,000 shares Purchase price per share: $13.79 per share Indirect IRA holdings after transaction: 11,005 shares +3 more

6 metrics

Common shares purchased 2,000 shares Purchased on August 27, 2026 by IRA account associated with Seth Lederman

Purchase price per share $13.79 per share Price for 2,000 Tonix common shares bought on August 27, 2026

Indirect IRA holdings after transaction 11,005 shares Tonix common stock held indirectly via IRA account following the purchase

Direct holdings 20,001 shares Tonix common stock reported as directly owned by Seth Lederman on August 27, 2026

Indirect Lederman & Co. holdings 1 share Tonix common stock held indirectly through Lederman & Co., with Lederman as a possible control person

Net buy shares 2,000 shares Net common shares bought across all reported transactions in this Form 4

Key Terms

indirect, IRA Account, control person, open market or private transaction

4 terms

indirect financial

"categorized as an indirect ownership purchase in an open-market"

IRA Account financial

"An IRA account associated with him purchased 2,000 shares"

control person regulatory

"he may be deemed a control person of this entity"

A control person is an individual or entity that can significantly influence a company’s decisions and direction through ownership, voting power, or contractual rights—think of them as the captain who can steer the ship. Investors care because a control person’s choices affect corporate strategy, board appointments, and transactions that can raise or lower a stock’s value, and they often carry additional legal responsibilities and disclosure requirements to protect other shareholders.

open market or private transaction financial

"Purchase in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TNXP CEO Seth Lederman report in this Form 4?

He reported that an IRA account associated with him purchased 2,000 shares of Tonix common stock on August 27, 2026 at $13.79 per share, categorized as an indirect ownership purchase in an open-market or private transaction.

How many TNXP shares did Seth Lederman buy and at what price?

An IRA account associated with Seth Lederman bought 2,000 shares of Tonix Pharmaceuticals Holding Corp. common stock at $13.79 per share on August 27, 2026, according to the Form 4 filing.

What are Seth Lederman’s indirect IRA holdings of TNXP after this transaction?

Following the August 27, 2026 purchase, the IRA account associated with Seth Lederman held 11,005 shares of Tonix common stock as indirect ownership, as reported in the Form 4.

What direct TNXP holdings did Seth Lederman report?

Seth Lederman reported 20,001 shares of Tonix common stock held as direct ownership as of August 27, 2026. This is disclosed separately from his IRA and Lederman & Co. indirect holdings.

What is the Lederman & Co. position in TNXP mentioned in the filing?

Lederman & Co. is reported as holding 1 share of Tonix common stock indirectly associated with Seth Lederman. A footnote states he may be deemed a control person of this entity.

Was this TNXP Form 4 trade under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox indicates false, meaning the reported August 27, 2026 purchase was not affirmatively disclosed as being made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/31/2026 - 08:00 AM EDT Accepted by SEC EDGAR 08/31/2026 - 08:00 AM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEDERMAN SETH

(Last)

(First)

(Middle)

C/O TONIX PHARMACEUTICALS HOLDING CORP.

200 CONNELL DRIVE, SUITE 3100

(Street)

BERKELEY HEIGHTS

NEW JERSEY

07922

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tonix Pharmaceuticals Holding Corp. [ TNXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $0.001 par value	08/27/2026		P		2,000	A	$13.79	11,005	I	By IRA Account⁽¹⁾
Common Stock, $0.001 par value								20,001	D
Common Stock, $0.001 par value								1	I	Lederman & Co.⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Reporting person may be deemed a control person of this entity.

	/s/ Seth Lederman	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR